Takeda Presents Full Data Set from Phase 3 ADVANCECIDP 1 Clinical Trial Investigating HYQVIA as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy CIDP at PNS Annual Meeting
TakedaTSE4502NYSETAK today announced full results from the pivotal Phase 3 ADVANCECIDP 1 clinical trial investigating HYQVIA Immune Globulin Infusion 10 Human with Recombinant Human Hyaluronidase as maintenance therapy in adult patients with chronic inflammatory demyelinating polyneuropathy CIDP.
Source: businesswireindia.com